Medical technology firm Brainlab AG has asked for bank proposals for its potential initial public offering in Frankfurt, ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

The restaurant group announced Tuesday that Jose Alberto Dueñas is stepping down. Chief financial officer Paul Carbone, a ...

Simpson Thacher partners offer IPO tips for private companies, noting that having an independent board and the correct ...

Nice One Beauty Digital Marketing Co. surged in its debut after a $320 million initial public offering in Riyadh, the latest ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

(Reuters) -Oilfield services provider Flowco Holdings on Tuesday said it is seeking a valuation of up to $2 billion in its ...

Quadrant Future Tek's IPO opened on January 7, aiming to raise ₹290 crore. It was 41.41 times subscribed by Day 2, with a ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

The IPO, with a face value of Rs 2 per equity share, comprises a fresh issue of up to Rs 1,000 crore and an offer for sale of ...

Standard Glass IPO concluded with 182.57 times subscription on the final day of offer on 8th January. The initial public offer got bids for 380 crore shares against 2.08 crore shares on offer, ...